Concepedia

Paul T. Kirschmeier

PT

89

Publications

12.2K

Citations

52

H-Index

1982

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Columbia University

AIL Research (United States)

Brigham and Women's Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

Paul T. Kirschmeier is an author at Dana-Farber Cancer Institute specializing in medicine, cell biology, and pharmacology.

Top concepts

MedicinePharmacologyCell BiologyTumor BiologyDrug DiscoveryNatural SciencesCancer ResearchBiochemistryPharmacotherapyOncology

Publications per year

1982–2020

89

Publications

89

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors

David B. Whyte, Paul T. Kirschmeier, Tish Hockenberry et al. · Journal of Biological Chemistry · 1997 · 872 citations · Full text

Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang et al. · Clinical Cancer Research · 2014 · 772 citations

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

Erick J. Morris, Sharda Jha, Clifford R. Restaino et al. · Cancer Discovery · 2013 · 673 citations · Full text

Pharmacotherapy, Tumor Biology, Drug Resistance +20

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 553 citations · Full text

Pharmacotherapy, Cancer Biology, Tumor Biology +16

<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte et al. · Cancer Discovery · 2017 · 552 citations · Full text

Rows per page

1–5 of 89